Trulicity Market Size to Reach USD 15.30 Billion by 2035 with Strong Demand for Metabolic Treatments | SNS Insider

By GlobeNewswire On May 4, 2026

U.S. Trulicity Market to Reach USD 4.87 Billion by 2035 Driven by Rising Diabetes Prevalence

Austin, May 04, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Trulicity Market size was valued at USD 7.03 Billion in 2025 and is expected to reach USD 15.30 Billion by 2035, growing at a CAGR of 8.16% during the forecast period 2026–2035.

The global Trulicity market is experiencing exponential growth due to the rise in cases of type 2 diabetes and obesity in different parts of the globe. The rising use of GLP-1 receptor agonists, wider uses in cardiovascular diseases, and technological developments in biologics-based drug delivery systems are some of the major forces behind the expansion of this market.

Trulicity Market Size and Forecast:

Market Size in 2025: USD 7.03 Billion
Market Size by 2035: USD 15.30 Billion
CAGR: 8.16% from 2026 to 2035
Base Year: 2025
Forecast Period: 2026–2035
Historical Data: 2022–2024

Get a Sample Report of Trulicity Market Growth Strategy @ https://www.snsinsider.com/sample-request/10030

U.S. Trulicity Market Insights

The U.S. Trulicity Market was valued at USD 2.39 billion in 2025 and is expected to reach USD 4.87 billion by 2035, growing at a CAGR of 8.22% over 2026–2035.

The US dominates the Trulicity market across the globe, attributed to the country’s high number of patients suffering from diabetes and obesity, use of GLP-1 drugs, advanced health care facilities, and favorable reimbursement schemes. Another factor driving the market is the increasing tendency among doctors to prescribe biological drugs and advancements in pen injector technology.

Rising Prevalence of Diabetes and Obesity to Drive Market Growth Globally

The global Trulicity market is primarily driven by increasing prevalence of type 2 diabetes and obesity. As metabolic diseases are recognized more and more commonly in clinical practice, the use of GLP-1 receptor agonists for glycemic control and cardiovascular disease risk reduction is gaining momentum.

The increasing use of Trulicity in conditions besides diabetes, supported by innovation in dosage forms, and also the sector prospects are a big factor to build the growing Trulicity marketplace. Growing safety, efficacy and compliance will contribute to its increased adoption in hospitals, retail pharmacies and at home.

Trulicity Market Segmentation Analysis:

By Therapeutic Application

On the basis of primary indication, Type 2 Diabetes led the global diabetes devices market in terms of revenue share with forecast revenue of US$61.97 billion in 2025 reaching a share of 59.38%. The overweight and weight loss patients are expected to be the fast-growing segments with a CAGR of approximately 9.68% in terms of revenue during the forecast period, which can be attributed to growing obesity prevalence globally as well as high adoption rates of GLP-1 drugs.

By Patient Demographics

The 18–64 years segment led the global market in terms of revenue share despite being relatively low compared to people over 65, accounting for around 54.69% in 2025; due to a high volume with diabetes and obesity within this age group. High-risk populations with obesity and diabetes will be the fastest growing subpopulations (CAGR 10.93% up to 2035).

By Distribution Channel

By 2025, hospital pharmacies accounted for largest managed distribution share across the revenue model at nearly 29.87%, attributed to higher number of prescriptions and organized treatment guidelines. So far as the distribution channel is concerned, online pharmacies are estimated to lead with a CAGR of roughly 9.60% over the progression period, attributable to increasing healthcare digitalization.

By Dosage & Formulation

Due to effectiveness and safety advantages, the 1.5 mg once weekly pen occupied ~24.56% of revenue share in 2025. The once weekly pen with a 4.5 mg dose will see the fastest CAGR over the forecast period, projected at roughly 9.70%, due to improved weight management and glycemic control outcomes.

Get Expert-Led Insights for Your Business Strategy — Connect with Analysts Now @ https://www.snsinsider.com/request-analyst/10030

Trulicity Market Regional Insights:

North America appears to be the dominant region and accounted for nearly 40.14% revenue share in 2025, owing to the established healthcare system coupled with high disease incidence rate & well-structured reimbursement landscape It is well positioned given the widely adopted GLP-1 based medicines and advances in biologics.

The most effective growth in the Asia Pacific area is due to a growing quantity of diabetic subjects, developing healthcare up healing facilities, and multiplied awareness about metabolic problems in rising nations which includes China and India with an anticipated CAGR of around 9.23% for the duration of 2018-2024.

Likewise, Europe is a huge market with robust healthcare infrastructure and favorable reimbursement trends. On the other hand, Latin America and Middle East & Africa continuing to reap growth due to improved appeal of healthcare deliverables along with chronic disease management programs.

Major Players Analysis Listed in the Trulicity Market Report:

Eli Lilly and Company
Novo Nordisk
Pfizer Inc.
Sanofi
AstraZeneca
Merck & Co.
Johnson & Johnson
GlaxoSmithKline plc
Boehringer Ingelheim
Amgen Inc.
Roche Holding AG
Novartis AG
Takeda Pharmaceutical Company
Bayer AG
Bristol Myers Squibb
Teva Pharmaceuticals
Cipla
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories
Lupin Limited

Trulicity Market Recent Developments:

In June 2025, Eli Lilly expanded its metabolic pipeline with tirzepatide (Mounjaro), strengthening its position in obesity and diabetes treatment alongside Trulicity.
In August 2025, Novo Nordisk expanded Wegovy’s approval for cardiovascular risk reduction, intensifying competition in the GLP-1 segment.

Purchase Comprehensive Trulicity Market Report – Single User PDF @ https://www.snsinsider.com/checkout/10030

Exclusive Sections of the Report (The USPs):

DISEASE PREVALENCE & EPIDEMIOLOGICAL BURDEN METRICS – helps analyze global diabetes and obesity prevalence and patient demographics.
DRUG PIPELINE & REGULATORY INSIGHTS – provides analysis of GLP-1 therapies, approvals, and ongoing clinical developments.
TREATMENT ADHERENCE & CLINICAL OUTCOMES – evaluates patient compliance, safety, and effectiveness of therapies.
REAL-WORLD EVIDENCE VS CLINICAL DATA – identifies gaps between trial outcomes and real-world usage.
MARKET ACCESS & REIMBURSEMENT ANALYSIS – assesses pricing, insurance coverage, and payer dynamics.
BIOSIMILAR & COMPETITIVE LANDSCAPE – evaluates impact of emerging competitors and patent expirations.

Trulicity Market Report Scope:

Report Attributes	Details
Market Size in 2025	USD 7.03 Billion
Market Size by 2035	USD 15.30 Billion
CAGR	CAGR of 8.16% From 2026 to 2035
Base Year	2025
Forecast Period	2026-2035
Historical Data	2022-2024
Key Segments	• By Therapeutic Application (Type 2 Diabetes (primary indication), Obesity/Weight Management (emerging use), Cardiovascular Risk Reduction, Metabolic Disorders (potential pipeline expansion), Others), • By Patient Demographics (Adults (18–64 Years), Geriatric Patients (65+ Years), Pediatric/Adolescent (off-label/clinical trials), High-Risk Populations (obese + diabetic overlap), Others), • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online/E-commerce Pharmacies, Specialty Clinics, Others), • By Dosage & Formulation (1.5 mg Once Weekly Pen, 0.75 mg Once Weekly Pen, 3.0 mg Once Weekly Pen, 4.5 mg Once Weekly Pen, Others)
Regional Analysis/Coverage	North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Demand for Industry Analysis: Our Comprehensive Report Trulicity Market @ https://www.snsinsider.com/reports/trulicity-market-10030

Other Related Trending Report:

GLP-1 Receptor Agonist Market

Type 2 Diabetes Market

Continuous Glucose Monitoring Market

Blood Glucose Monitoring Device Market

BRIC Diabetes Care Devices Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Data Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.